Safety and efficiency of Wharton’s Jelly-derived mesenchymal stem cell administration in patients with traumatic brain injury: First results of a phase I study

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

1143

Figures (1-3)

178

Tables (1-16)

144

Sum=1503

Publishing Process of This Article

Item

Count

Browse

Download

179

Sum=228

Jun 26, 2024 (publication date) through Dec 26, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Stem Cells

ISSN

1948-0210

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Clinical Trials Study

World J Stem Cells. Jun 26, 2024; 16(6): 641-655
Published online Jun 26, 2024. doi: 10.4252/wjsc.v16.i6.641

Table 7 Friedman test results of the changes observed in the Modified Ashworth Score right values of the patients before and after the intervention

Citation: Kabatas S, Civelek E, Boyalı O, Sezen GB, Ozdemir O, Bahar-Ozdemir Y, Kaplan N, Savrunlu EC, Karaöz E. Safety and efficiency of Wharton’s Jelly-derived mesenchymal stem cell administration in patients with traumatic brain injury: First results of a phase I study. World J Stem Cells 2024; 16(6): 641-655
URL: https://www.wjgnet.com/1948-0210/full/v16/i6/641.htm
DOI: https://dx.doi.org/10.4252/wjsc.v16.i6.641